Sort
39,280 grants matching “leukemia”
STAT3 inhibition as a therapeutic strategy against MDS stem cells
$531,973Amit Verma · Albert Einstein College Of Medicine · R01 · FY2020 · HL
STAT3 inhibition as a therapeutic strategy against MDS stem cells
$531,973Amit Verma · Albert Einstein College Of Medicine · R01 · FY2019 · HL
Inflammation as determinant of clonal selection in MPN progression
$531,949Nadia Carlesso · Beckman Research Institute/City Of Hope · R01 · FY2020 · HL
Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia
$531,920Ellen Van Der Plas · Arkansas Children'S Hospital Res Inst · R37 · FY2023 · CA
Organizing and Reorganizing Human Testis Development In Vitro
$531,820Kyle E Orwig · Magee-Women'S Res Inst And Foundation · R01 · FY2025 · HD
Selectively Targeting Oncogenic NRAS in Cancer
$531,791Kevin M Shannon · University Of California, San Francisco · R01 · FY2021 · CA
Targeting Tumors with NF1 Loss
$531,751Yolanda Sanchez · Dartmouth College · R01 · FY2019 · NS
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias
$531,691Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
$531,560Arti Hurria · Beckman Research Institute/City Of Hope · R01 · FY2011 · AG
Naive T cell depletion to prevent graft-versus-host disease
$531,554Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2015 · HL
Innate and adaptive immunity in celiac disease
$531,480Bana Jabri · University Of Chicago · R01 · FY2018 · DK
Innate and adaptive immunity in celiac disease
$531,480Bana Jabri · University Of Chicago · R01 · FY2015 · DK
Innate and adaptive immunity in celiac disease
$531,480Bana Jabri · University Of Chicago · R01 · FY2019 · DK
Innate and adaptive immunity in celiac disease
$531,480Bana Jabri · University Of Chicago · R01 · FY2017 · DK
Innate and adaptive immunity in celiac disease
$531,480Bana Jabri · University Of Chicago · R01 · FY2016 · DK
Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells
$531,448Christopher A Pennell · University Of Minnesota · R01 · FY2023 · CA
Structural surfaceomics to probe conformation-selective immunotherapy targets
$531,377Arun P. Wiita · University Of California, San Francisco · R01 · FY2025 · CA
Targeting DNA repair to eradicate TKI-refractory/resistant CML
$531,250Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2015 · CA
Targeting DNA repair to eradicate TKI-refractory/resistant CML
$531,250Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2016 · CA
GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer
$531,117Samuel Volchenboum · University Of Chicago · U01 · FY2022 · CA
Phase separation-induced nuclear organization in ALT Cancer
$530,948Huaiying Zhang · Carnegie-Mellon University · U01 · FY2022 · CA
Phase separation-induced nuclear organization in ALT Cancer
$530,948Huaiying Zhang · Carnegie-Mellon University · U01 · FY2021 · CA
Phase separation-induced nuclear organization in ALT Cancer
$530,948Huaiying Zhang · Carnegie-Mellon University · U01 · FY2020 · CA
lncRNA regulation of glioblastoma progression and therapeutic resistance
$530,805Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · NS
Metabolic enforcement of selection in anti-DNA B cells vs. antigen-specific B cells
$530,791Emily K. Moser · University Of Florida · R01 · FY2024 · AI